Bridgeway Capital Management LLC cut its stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 35.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 184,155 shares of the specialty pharmaceutical company's stock after selling 102,500 shares during the quarter. Bridgeway Capital Management LLC owned 1.31% of Cumberland Pharmaceuticals worth $436,000 as of its most recent SEC filing.
Cumberland Pharmaceuticals Price Performance
CPIX traded up $0.28 during midday trading on Thursday, reaching $5.24. 12,766 shares of the company's stock were exchanged, compared to its average volume of 860,652. Cumberland Pharmaceuticals Inc. has a 1-year low of $1.04 and a 1-year high of $7.25. The stock has a market capitalization of $73.19 million, a PE ratio of -6.81 and a beta of -0.35. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The business's 50-day moving average price is $4.64 and its 200 day moving average price is $3.38.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.
Analyst Ratings Changes
Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 8th.
Check Out Our Latest Research Report on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Company Profile
(
Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Further Reading
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
